Induction of nociceptive stimulus in TMJ region : minimum effective concentration of piperine in normality, local chronic inflammation and chronic stress conditions by Martins, Ana Paula Varela Brown, 1979-
i 
 
 
 
 
 
 
 
 
 
 
“Indução do Estímulo Nociceptivo na Região da ATM: mínima 
concentração efetiva de Piperina em Condições de Normalidade, 
Inflamação Local Crônica e Estresse Crônico”  
 
“Induction of nociceptive stimulus in TMJ region: minimum effective concentration of 
Piperine in Normality, Local Chronic Inflammation and Chronic Stress Conditions” 
 
 
 
 
 
Piracicaba 
2013 
ANA PAULA VARELA BROWN MARTINS 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
                          
 
 
Ana Paula Varela Brown Martins 
 
 
Indução do Estímulo Nociceptivo na Região da ATM: mínima concentração efetiva de 
Piperina em Condições de Normalidade, Inflamação Local Crônica e Estresse Crônico 
“Induction of nociceptive stimulus in TMJ region: minimum effective concentration of 
Piperine in Normality, Local Chronic Inflammation and Chronic Stress Conditions” 
 
 
 
  
 
 
 
 
 
 
 
 
 
Piracicaba, 2013 
Tese de Doutorado Apresentada à Faculdade de Odontologia 
de Piracicaba da Unicamp para Obtenção do Título de Doutora 
em Clínica Odontológica na Área de Prótese Dental 
 
Doctorate Thesis Presented to the Piracicaba Dental School 
to Obtain the Ph.D. Grade in Dental Clinic in the Dental 
Prosthesis Area 
 
Orientadora: Profa. Dra. Célia Marisa Rizzatti Barbosa 
Este exemplar corresponde à versão final da Tese 
defendida pela aluna, e orientada pela Profa. Dra. 
Célia Marisa Rizzatti Barbosa  
Assinatura da Orientadora 
_______________________________ 
Universidade Estadual de Campinas 
Faculdade de Odontologia de Piracicaba 
Ficha catalográfica
Universidade Estadual de Campinas
Biblioteca da Faculdade de Odontologia de Piracicaba
Marilene Girello - CRB 8/6159
    
  Martins, Ana Paula Varela Brown, 1979-  
 M366i MarIndução do estímulo nociceptivo na região da ATM : mínima concentração
efetiva de piperina em condições de normalidade, inflamação local crônica e
estresse crônico / Ana Paula Varela Brown Martins. – Piracicaba, SP : [s.n.], 2013.
 
   
  MarOrientador: Célia Marisa Rizzatti Barbosa.
  MarTese (doutorado) – Universidade Estadual de Campinas, Faculdade de
Odontologia de Piracicaba.
 
    
  Mar1. Articulação temporomandibular. I. Rizzatti-Barbosa, Célia Marisa,1957-. II.
Universidade Estadual de Campinas. Faculdade de Odontologia de Piracicaba. III.
Título.
 
Informações para Biblioteca Digital
Título em outro idioma: Induction of nociceptive stimulus in TMJ region : minimum effective
concentration of piperine in normality, local chronic inflammation and chronic stress conditions
Palavras-chave em inglês:
Temporomandibular joint
Área de concentração: Prótese Dental
Titulação: Doutora em Clínica Odontológica
Banca examinadora:
Célia Marisa Rizzatti Barbosa [Orientador]
Cinara Maria Camparis
Luciano Castellucci Barbosa
Eduardo Dias de Andrade
Antônio Pedro Ricomini Filho
Data de defesa: 07-08-2013
Programa de Pós-Graduação: Clínica Odontológica
Powered by TCPDF (www.tcpdf.org)
iv
v 
 
 
vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedico este trabalho a minha FAMÍLIA pelo 
incentivo para meu crescimento profissional, 
estímulo nos momentos precisos e 
compreensão da minha ausência durante este 
período. 
vii 
 
AGRADECIMENTOS 
  
A Deus, pelas oportunidades dadas, proteção e orientação, especialmente nesses 
anos longe de casa para obtenção desta conquista.  
À Universidade Estadual de Campinas, na pessoa de seu reitor Prof. Dr. José 
Tadeu Jorge, pela administração desta instituição. 
À Faculdade de Odontologia de Piracicaba da Universidade Estadual de 
Campinas (FOP/Unicamp), na pessoa de seu diretor Prof. Dr. Jacks Jorge Junior, pela 
utilização de suas instalações.  
À Profa. Dra. Renata Cunha Matheus Rodrigues Garcia, Coordenadora 
Geral dos cursos de pós-graduação da FOP/Unicamp.  
Ao Prof. Dr. Márcio de Moraes, Coordenador do Programa de Pós-Graduação 
em Clínica Odontológica.  
À Fundação de Amparo à Pesquisa do Estado de São Paulo, pela concessão 
de Bolsa de Doutorado (2012/07964-2). 
À minha FAMÍLIA: meus pais, Miriam Cléa Martins e Paulo Martins Filho; 
meus irmãos, Paulo Neto e Ana Carina Maia; cunhado: Alexandre Maia e sobrinhos muito 
queridos: Rafael Maia, Felipe Maia; Eunice Lopes e Emília Araújo; avós, Dalva Passos e 
José Moacyr da Cunha Passos (in memoriam); pelo apoio e estímulo; amor e carinho 
incondicionais e por acreditarem no meu crescimento profissional.  
Aos meus queridos amigos: Luciana Valadares, Andréa Lira, Iza Peixoto, 
pelos primeiros incentivos a vir para Piracicaba; Fabiana Praia, Ediane Lustosa, Ana 
Verena Gonçalves, Blandina Brandão, José Maurício Brandão, Lívia Carvalho, por 
torcerem pelo meu crescimento e a todos os meus colegas e amigos da graduação. Aos 
meus amigos baianos, residentes em Piracicaba: Luana Bastos, Lívia Aguilera, Frederico 
Sampaio e Manoela Carrera. Às minha amigas do quarteto fantástico: Luana de Aquino, 
Milene de Oliveira e Celina de Abreu pelos momentos de descontração, de superação, 
ensinamentos e por todo o suporte e que mesmo a distância o carinho e a amizade 
permaneceram. Janice Simpson, Maíra Silva e Brunna Moreira pelos momentos 
compartilhados e pela amizade sincera; e aos amigos: Carolina Meloto, William 
viii 
 
Custódio, Antônio Pedro Ricomini Filho pelo apoio, desabafos e ensinamentos. Às 
minhas queridas amigas, com as quais formamos um grupo muito unido, Andréa Araújo 
Vasconcellos, Indira Cavalcanti, Germana Camargos, Larissa Vilanova, Priscilla 
Lazari, Sheila Rodrigues, Sílvia de Lucena, meu agradecimento por toda ajuda oferecida 
e pelos momentos maravilhosos e divertidos que passamos juntas, minha família 
piracicabana. A todos os amigos e colegas de laboratório, em especial Cindy Dodo, Letícia 
Machado Gonçalves, Lis Meirelles e Paula Furlan Bavia.  
Aos meus eternos mestres: Luciano Castellucci, Vagner Mendes, Armando 
Prado, Guilherme Meyer, Analu Andrade, Vera Rocha, por despertarem em mim o 
amor pela prótese.  
Aos funcionários do Biotério, Daniely Libório Machado, Wanderley Vieira e 
Floriza Aparecida Godoy, pelo suporte oferecido durante o trabalho com os animais. A 
Eliete Marim, secretária do Departamento de Prótese e Periodontia, pela disponibilidade 
em ajudar. A Gislaine Piton, técnica do laboratório de PPR, pelo apoio incondicional, 
incentivo e acolhimento.  
Aos Professores do Departamento de Prótese Dental, em especial aos 
Professores de Prótese Parcial Removível, Profa. Altair Cury, Profa. Renata Cunha, 
Prof. Wander José da Silva por todo ensinamento.  
Ao Laboratório de Fisiologia, em nome da Profa. Dra. Juliana Napimoga, 
pela permissão na utilização da estrutura física e à colega Cristina Gomes de Macedo 
Maganin, pelo ensinamento e ajuda.  
Às amigas, Noélia Sacramento (in memoriam), Maria José Almeida, Railda 
Silva, Raimunda Planzo, pelas orações e que mesmo de longe torcem pelo meu 
crescimento profissional. 
 
 
 
 
ix 
 
AGRADECIMENTO ESPECIAL 
 
À minha orientadora, Profa. Dra. Célia Marisa Rizzatti Barbosa, pelas 
orientações, ensinamentos, paciência, confiança e compreensão, exemplo de 
profissionalismo e entusiasmo pela profissão. Deus sempre coloca pessoais especiais perto 
de mim, e com a senhora, minha “Ori” querida, não seria diferente, exemplo de mulher, 
mãe e profissional forte e dedicada e que tornou minha permanência em Piracicaba mais 
agradável e de aprendizado constante. Muito obrigada por tudo.  
 
"O valor das coisas não está no tempo que elas duram, 
mas na intensidade com que acontecem.  
Por isso existem momentos inesquecíveis, 
coisas inexplicáveis e pessoas incomparáveis." 
Chico Xavier 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“O que vale na vida não é o ponto de partida e sim a caminhada. 
Caminhando e semeando, no fim terá o que colher”. 
Cora Coralina. 
xi 
 
RESUMO 
 
A disfunção temporomandibular pode afetar músculos mastigatórios, 
articulação temporomandibular (ATM) ou ambos; possui elevada prevalência nas mulheres 
e sintoma mais comum é a dor. Foi proposto determinar mínima concentração efetiva da 
piperina para ativar o Potencial Receptor Transiente Vanilóide da subfamília 1 (TRPV1) na 
região da ATM direita de ratas Wistar, nas condições: normalidade, inflamação crônica na 
ATM, estresse crônico e associação destas. Foram desenvolvidos 2 estudos experimentais, 
randomizados, duplo-cegos (protocolo nº 2633-1). No estudo I, 48 animais foram 
distribuídos aleatoriamente em seis grupos, e cada grupo recebeu 30 µl na ATM de uma das 
soluções: solução padrão (10% de álcool etílico, 10% de Tween 80 e 80% de solução salina 
estéril) ou 1, 2, 3, 4 e 5 µg de piperina diluída em 100 ml da solução padrão. No estudo II, 
144 ratas foram aleatoriamente distribuídas em grupos: A - inflamação crônica na ATM 
direita induzida pelo Adjuvante Completo de Freund; B - estresse crônico provocado pelo 
modelo crônico de estresse; C - associação dessas condições. Esses grupos foram 
subdivididos (n = 8), e injetados na ATM 30 µl das mesmas soluções descritas 
previamente. Nos estudos, as ratas, na fase diestro do ciclo hormonal, após injeção de uma 
das soluções, foram avaliadas quanto ao comportamento nociceptivo, que consistia em 
quantificar o número de vezes que as ratas levantaram a cabeça abruptamente e tempo 
dispendido, em segundos (s), para coçar a região orofacial. Cada levantar da cabeça seguiu 
padrão uniforme de 1 segundo de duração, assim, os comportamentos foram expressos em 
função do tempo, possibilitando somatória. Para comparação estatística, foi empregado 
análise da variância e teste de Tukey-Kramer (P< 0,05). No estudo I, existiu diferença 
significante para comportamento de coçar a região orofacial entre os grupos de 2 µg e 5 µg 
(100,37 ± 63,81 s; 100,0 ± 60,5 s, respectivamente) e o controle (33.37 ± 18,48 s), e 
somatória dos comportamentos entre 2µg (130,87 ± 257,88 s) e o controle (62.75 ± 14,81 
s). No estudo II, no grupo A, houve diferenças estatísticas significativas para os 
comportamentos de levantar a cabeça no grupo de 5µg (69,5 ± 16,44 s) e o controle (41,13 
± 15,06 s); coçar a região orofacial entre 4µg (51,5 ± 28,73 s) e o controle (14,71 ± 7,54 s), 
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e na somatória entre 4 e 5µg (105,37 ± 22,64 s; 115,50 ± 35,14 s, respectivamente) e o 
controle (52,86 ± 17,46 s). No grupo B, nos comportamentos de levantar a cabeça entre 4 
µg (85,87 ± 19,21 s) e o controle (49,87 ± 10,70 s); coçar a região orofacial entre 5 µg 
(48,25 ± 27,25 s) e o controle (35,75 ± 12,69 s). No grupo C, não houve diferença 
significante nos subgrupos. Assim, 0,02 µg/ml de piperina mostrou-se a concentração 
mínima eficiente para provocar estímulo nociceptivo na condição de normalidade; a 
solução de 0,04 µg/ml de piperina, para os grupos de inflamação crônica articular e de 
estresse crônico e para o grupo de associação das condições não foi evidenciado diferença 
estatística significante. 
 
 
Palavras-Chaves: Articulação temporomandibular – Dor facial – Comportamento 
animal – Pimenta do Reino – Estresse psicológico 
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ABSTRACT 
 
Temporomandibular Dysfunction may affect the masticatory muscles, 
temporomandibular joint (TMJ) or both, has high prevalence in women and most common 
symptoms is pain. It was proposed to determine minimal effective concentration of piperine 
to activate the transient receptor potential vanilloid subfamily 1 (TRPV1) in the right TMJ 
in Wistar female rats under the conditions: normal, chronic inflammation in the TMJ, 
chronic stress and inflammation and stress combination. It was developed two randomized 
double-blind experimental studies (n. 2633-1). In study I, 48 animals were randomly 
divides into six groups, each group received 30 µl into the TMJ one of this solutions: 
standard solution (80% sterile saline, 10% Tween 80 and 10% ethyl alcohol) or 1, 2, 3, 4 
and 5 μg of piperine diluted in 100 ml of standard solution. In study II, 144 rats were 
randomly divided into groups: A – chronic inflammation in the right TMJ induced by 
Freund’s Complete Adjuvant; B – chronic stress caused by chronic stress model; C – 
association of these conditions. These groups were divided (n = 8), and it was injected into 
the TMJ 30 µl of the same solutions as previously describe. In both studies, rats in diestrous 
phase of the hormonal cycle, after injection of the solution, were assessed for nociceptive 
behavior, which consisted in quantify how many times the rats flinched its head and the 
time spent, in seconds (s), to rub the orofacial region. Each head flinch followed uniform 
pattern of 1 second duration, and the behaviors were expressed as time function, allowing 
the sum. For statistical comparison, it was used variance analysis and Tukey-Kramer 
(P<0.05). In study I, there was a significant difference for rubbing orofacial region between 
groups of 2 μg and 5 μg (100,37 ± 63,81 s, 100 ± 60,5 s, respectively) and control (33,37 ± 
18,48 s), and the sum of the behaviors between 2μg (130,87 ± 257,88 s) and control (62,75 
± 14,81 s). In study II, in group A, there were statistical differences for head flinch behavior 
between 5μg (69,5 ± 16,44 s) and control (41,13 ± 15,06 s) groups; for rubbing orofacial 
region between 4μg (51,5 ± 28,73 s) and control (14,71 ± 7,54 s), and for the sum, among 4 
and 5μg (105,37 ± 22,64 s, 115,50 ± 35,14 s, respectively) and controls (52,86 ± 17,46 s). 
In group B, for head flinching behavior there was significant difference between 4 μg 
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(85,87 ± 19,21 s) and control (49,87 ± 10,7 s); rubbing orofacial region, between 5 μg 
(48,25 ± 27,25 s) and control (3,.75 ± 12,69 s). In group C, there was no significant 
difference in the subgroups. Thus, 0,02 μg/ml of piperine showed the lowest concentration 
effective to cause noxious stimulation in normal condition, the solution of 0,04 μg/ml of 
piperine, for groups of chronic joint inflammation and chronic stress and for association 
conditions group there was not statistical significant difference.   
 
Key-Wods: Temporomandibular Joint – Facial Pain – Animal Behavior – Black 
Pepper – Psychological Stress 
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Introdução 
 
A disfunção temporomandibular (DTM) é uma patologia que pode acometer o 
sistema estomatognático e envolve músculos mastigatórios, articulações 
temporomandibulares (ATM), músculos cervicais e outras estruturas correlatas, como 
vasos sanguíneos e estruturas nervosas (LeResche & Drangsholt, 2008). Dentre os sinais e 
sintomas mais prevalentes desta disfunção encontram-se desvio e limitação de movimentos 
mandibulares e cervicais, especialmente durante mastigação e abertura bucal, ruídos 
condilares, desconforto nas estruturas envolvidas, e com certa frequência intensa dor 
crânio-cervical (LeResche & Drangsholt, 2008). Estas características da DTM aliadas a 
outros sinais também prevalentes, como hiperatividade muscular e o aparecimento de 
pontos-gatilho miofasciais nos músculos mastigatórios, desencadeiam fortes dores locais e 
referidas capazes de conduzir a importantes limitações físicas, psíquicas e sociais ao 
paciente.  
Apesar da fisiopatologia da dor presente nas DTM ser pouco compreendida, é 
considerada uma condição clínica relevante, principalmente devido à sua elevada 
prevalência (Lipton et al, 1993; LeResche et al, 2005; Isong et al, 2008; LeResche & 
Drangsholt, 2008). Com relação à prevalência da DTM, estudos epidemiológicos apontam 
uma ampla variação entre 11 a 50%, refletindo as diferenças de metodologia entre os 
mesmos (Lipton et al, 1993; LeResche, 1997; Manfredini et al, 2006). No Brasil foi 
comprovado que 39,2% dos indivíduos adultos apresentam um dos sintomas da DTM, 
como sons articulares, dor articular ou dos músculos mastigatórios, e dificuldade de 
abertura da boca e destes, 25,5% estão relacionados à dor (Gonçalves et al, 2010).  
Fatores de risco, como condições de dor pré-existente, hormônios sexuais, fatores 
psicológicos e depressão parecem contribuir para a progressão e exacerbação da 
sintomatologia dolorosa da DTM (Suvinen et al, 1997; Drangsholt & LeResche, 1999). 
Estudos clássicos investigaram a relação entre estresse psicológico e DTMs (Parker, 1990; 
Grzesiak, 1991; Vanderas, 1994; Wexler & Steed, 1998). Parker (1990) considerou que 
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influência do estresse sobre a DTM seria explicada pelo aumento da tensão muscular 
durante as condições emocionais estressantes. Entretanto, também se considera que a 
disfunção muscular induzida por trauma local (Rizzatti-Barbosa et al, 2010; Farias Neto et 
al, 2012) ou estresse (Uhac et al, 2003) secundariamente produzirá alterações nas ATM, 
causando modificações sensíveis na biomecânica articular, promovendo microtraumas à 
cápsula e disco articulares, com consequente aumento  na percepção de dor. Inicialmente, 
acreditava-se que a influência do estresse no desenvolvimento da DTM estivesse 
relacionada com hiperatividade muscular crônica recorrente, que progressivamente 
danificava os tecidos (Laskin, 1969). Hoje se sabe que o estresse é capaz de afetar 
profundamente os processos biológicos de transmissão e percepção da dor (Vedolin et al, 
2009). Assim, respostas adaptativas inadequadas a condições de estresse podem agir como 
auto-estressores (a dor orofacial é um forte elemento estressor), alimentando um ciclo 
vicioso de dor-estresse-dor (Vedolin et al, 2009). As condições psicológicas envolvidas no 
estresse ainda não são totalmente compreendidas, e como os fatores psicológicos per si 
influenciam na fisiopatologia da DTM ou como refletem no impacto da doença em um 
indivíduo ainda é um fato desconhecido pela ciência (Vedolin et al, 2009).  A compreensão 
desta influência é dificultada pela inviabilidade do uso de modelos experimentais que 
evidenciem esta fisiopatologia em humanos, cujo comportamento frente ao estresse não é o 
mesmo daquele observado nos animais.  Por esta razão, a carência de estudos humanos, por 
questões éticas, incita o aprimoramento dos modelos animais que mais se aproximem da 
realidade clínica. Assim sendo, a correlação entre estudos clínicos e experimentos em 
modelos animais, pesquisas translacionais, torna-se cada vez mais necessária frente às 
respostas exigidas para a compreensão e consequente intervenção no processo de 
desencadeamento e manutenção da dor, de modo particular, aquela envolvida nas DTM 
(Roveroni et al, 2001).  
Pesquisas comprovaram, sob determinadas condições experimentais (estresse agudo 
e crônico), os efeitos hiperálgicos do estresse em animais (Vidal & Jacob, 1982; Satoh et al, 
1992; Quintero et al, 2000; Imbe et al, 2004), contrariando outros estudos que 
demonstraram que o estresse promove analgesia (Wiedenmayer & Barr, 2000;  Lapo et al., 
2003). Experimentos confirmaram que exposição a um estresse emocional agudo, como a 
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exposição sistemática a novos ambientes, é capaz de produzir hiperalgesia imediata e 
transitória (Vidal & Jacob, 1982), enquanto que o estresse prolongado induz hiperalgesia 
que persiste por até 28 dias após a suspensão do estresse crônico (Torres et al, 2003). 
Modelos experimentais de indução de dor e/ou inflamação em ratos utilizando óleo 
de mostarda ou formalina, por exemplo, já foram desenvolvidos e validados. Por meio 
destes modelos, foi possível estudar e compreender alguns dos mecanismos envolvidos nas 
condições de dor craniofacial superficial e profunda, algumas das mudanças nos sistema 
nervoso central e periférico, e o envolvimento dos diversos mediadores inflamatórios neste 
processo (Fiorentino et al, 1999; Roveroni et al, 2001; Gameiro et al, 2005; Bonjardim et 
al, 2009). Entretanto, esses modelos foram desenvolvidos utilizando animais do gênero 
masculino.  O desenvolvimento de modelos específicos em fêmeas torna-se interessante, 
pois parece existir uma diferença na percepção à dor entre os gêneros pela influência dos 
hormônios sexuais, tanto em humanos quanto em animais.  Está comprovado que presença, 
duração e severidade da dor na DTM são maiores em mulheres (Flake et al, 2006; 
LeResche & Drangsholt, 2008), o que sugere a influência dos hormônios femininos, 
particularmente o estrógeno, na fisiopatologia da dor na DTM (Flake et al., 2006), por 
estarem ambos, níveis maiores de estrógeno e maior prevalência da DTM, mais presentes 
durante a fase reprodutiva da mulher (LeResche et al, 1997; Carlsson, 1999). As possíveis 
explicações sobre a influência deste hormônio no desenvolvimento e manutenção da DTM, 
é que ele participe na modulação do processo inflamatório associado ao dano local da 
ATM, ou no aumento da excitabilidade das terminações na articulação regulando a 
expressão e liberação local de neuropeptídeos inflamatórios (Flake et al, 2006). Em 
trabalhos anteriores, foi evidenciado que polimorfismos relacionados aos receptores de 
estrógeno são mais prevalentes nas mulheres que sentem mais dor diante do quadro clínico 
de DTM
1
 (Rizzatti-Barbosa et al, 2009; Meloto et al, 2011).  
Agentes irritantes naturais, por desencadearem um poderoso estímulo nocivo em 
neurônios sensoriais primários, podem ser empregados em experimentos em animais no 
intuito de avaliar o comportamento nociceptivo (Geppetti & Trevisan, 2004; Martins et al, 
                                                 
1 Projeto FAPESP # 2004/07258-4: “Análise do Polimorfismo em gene receptor α de estrógeno em mulheres com sinais e sintomas de 
desordem temporomandibular”. 
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2011). A piperina (1-peperoilpiperidina) é um alcalóide que consiste no principal princípio 
ativo da pimenta do reino (Piper nigrum), e que promove uma sensação de ardência 
supostamente mediada pela ativação do receptor de potencial transiente vanilóide, membro 
da subfamília vanilóide 1 (TRPV1) ((McNamara et al, 2005).  Este foi inicialmente descrito 
como um receptor para capsaicina (Fu et al, 2010), mas sabe-se que a piperina também 
compartilha sítios de ligação em comum a outros produtos naturais de plantas, como a 
resiniferatoxina (Liu & Simon, 1996; Szallasi & Blumberg, 1999) e da sua habilidade em 
ativar correntes em neurônios sensoriais de ratos, isolados do gânglio trigeminal (Liu & 
Simon, 1996; Szallasi & Appendino, 2004).  
Além da diferença estrutural pela substituição do grupo vanilil pelo metilenodioxi 
(McNamara et al, 2005; Szallasi, 2005), a piperina é mais eficiente em induzir 
dessensibilização dos receptores (McNamara et al, 2005). Foi comprovado que as ações da 
piperina sobre o TRPV1 são coerentes com as ações de um agonista para este receptor, mas 
também que ela exibe uma clara propensão para induzir dessensibilização do receptor 
(McNamara et al, 2005). Acredita-se que o TRPV1 funcione como um integrador 
molecular de estímulos nocivos, incluindo calor, ácidos, poluentes com mudança elétrica 
negativa, e substâncias endógenas pró-inflamatórias (Szallasi & Blumberg, 1999). Expresso 
em tecidos neuronais, tais como medula espinhal (primariamente em fibras eferentes 
sensoriais) hipotálamo, hipocampo e substância negra, e não-neuronais, tais como 
mastócitos e glia (Cortright & Szallasi, 2004). O TRPV1 também é altamente expresso em 
neurônios primários sensoriais, fibras A-δ e C, nociceptores polimodais que respondem a 
diversos estímulos químicos, mecânicos e térmicos (Geppetti & Trevisan, 2004). Linfócitos 
e mastócitos também expressam o TRPV1, evidenciando uma interação entre os sistemas 
nervoso e imune (Szallasi, 2005). 
Mecanismos ainda pouco esclarecidos, mantêm o TRPV1 no estado inativo 
(Szallasi, 2005). Possivelmente, o TRPV1 esteja sob o controle inibitório do 
fosfatidilinosito (4,5)-bisfosfato [Ptd Ins (4,5) P2], que na presença de agonistas, 
fosfoflipase C (que cliva o Ptd Ins (4,5) P2) ou proteínas cinases (especialmente a cinase C) 
podem ativar esse receptor e acoplá-lo a outros receptores da dor, como o receptor da 
bradicinina B2 (Di Marzo, 2002). A ativação do TRPV1 resulta em rápido aumento dos 
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níveis de Ca
2+
 intracelular (Cortright & Szallasi, 2004) e esse evento iônico resulta em um 
efeito excitatório dos terminais de neurônios sensoriais primários com a subsequente 
despolarização da fibra nervosa e o início da propagação do potencial de ação (Geppetti & 
Trevisan, 2004). Influxo de Ca
2+
 em terminações nervosas, impulsionada tanto pela 
condução antidrômica do potencial de ação ou diretamente pela propagação do TRPV1, 
provoca a liberação de neuropeptídeos, incluindo peptídeo relacionado ao gene da 
calcitonina (PRGC) e as taquicininas, substância P (SP) e neurocinina A (NKA) (Geppetti 
& Trevisan, 2004). A liberação de SP e de PRGC pode contribuir para o componente 
neurogênico da inflamação, por terem propriedades pró-inflamatórias (Khan et al, 2008). 
Esses mediadores podem provocar vasodilatação, extravasamento plasmático, liberação de 
histamina, prostaglandina E2 (PGE2), citocinas (interleucina-1, interleucina-6, fator de 
necrose tumoral-α) contribuindo para a dor e inflamação neurogênica (Khan et al, 2008). 
Foi comprovada a participação do TRPV1 no desenvolvimento de hiperalgesia pós-
inflamatória, pois a expressão desse receptor encontrar-se aumentada em várias desordens 
humanas como doenças inflamatórias intestinais e trato urinário, e condições de dor crônica 
(Szallasi & Appendino, 2004).  
Deste modo, o objetivo do presente estudo foi elaborar modelos experimentais de 
dor na região da ATM de ratas, utilizando solução de piperina em diferentes concentrações 
para determinar sua mínima concentração efetiva para provocar o estímulo nociceptivo, sob 
as seguintes condições: normalidade, presença de inflamação crônica na ATM, condição de 
estresse crônico e a associação de ambas as condições, avaliando o comportamento 
nociceptivo do animal no curso do tempo. Este experimento evidenciou a possibilidade de 
estimular o TRPV1 na região da ATM através a piperina, demonstrando o envolvimento 
deste receptor no mecanismo da dor nesta articulação, e poderá servir de base para o 
desenvolvimento de fármacos específicos e de ação direta para o alívio da dor nas DTM.  
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Piperine solution: effective concentration to promote nociception in 
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Abstract: The objective of this study was to develop an animal model of orofacial pain in 
temporomandibular joint region in females Wistar rats using different concentrations of 
piperine in order to determinate its minimum effective concentration to induce nociception. 
Forty eight Wistar female rats were randomly divided in six groups (n=8), that received an 
injection in the right TMJ region of 30 µl of one of the following solutions: control group – 
ethyl alcohol, Tween 80, sterile saline and the other experimental groups: 1; 2; 3; 4 or 5 µg 
of piperine diluted in 100 ml of ethyl alcohol, Tween 80, sterile saline. The rats had their 
hormonal cycle analyzed and the animals in diestrous cycle were immediately evaluated for 
the nociceptive behavior, after the injection of one of the solutions. The nociceptive 
behavior consisted in counting how many times the animals flinched their head and how 
long they rubbed their orofacial region. As the first behavior followed a uniform pattern of 
1 movement per second, both behaviors were expressed in seconds. The data were 
submitted to the one-way ANOVA and Tukey-Kramer´s test (post-hoc, P<0.05). The 
higher means (±SE) for time (seconds) of orofacial rubbing were gotten in groups II 
(100.37 ± 30.42) and V (100 ± 27.82); for the head flinches, the highest mean was in group 
III (44.87 ± 4.76); finally, the highest mean for the sum of both behavior was gotten in 
group II (130.87 ± 27.53) with significant difference when comparing with the control 
group.. The results suggest that induced pain in the TMJ region with 0,02 µg/ml has been 
proved to be the minimum effective concentration to cause pain in this region and also it 
can be used as a valuable model in the study of orofacial pain. 
 
Keywords: Piperine - nociceptive behavior - Temporomandibular Joint 
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Introduction 
The prevalence of chronic pain in the population is high (8-15%) (LeResche et 
al, 2003) and its mechanisms are not still completely understood. Experiments in animal 
models have been important to elucidate its pathophysiology and modulation (LeResche et 
al, 2003), and to ensure the effectiveness of treatment for Temporomandibular Disorders 
(TMD). Higher prevalence in women, especially during the reproductive age, suggests the 
influence of female sex hormones in the painful symptoms of TMD (Flake et al, 2005). It 
was proved that TMD pain in women is highest at times of lowest estrogen during the 
hormonal cycle (LeResche et al, 2003).  
Studies using substances that cause noxious stimuli (glutamate, mustard oil, 
formalin, capsaicin) were also proposed mainly to verify the effectiveness of determined 
drugs. Each substance has specific mechanism on the nociceptive nerve fibers endings, 
either to provoke local inflammation or increase muscle activity, and also to promote the 
conduction of noxious stimulation and its processing in higher centers related to pain. 
Piperine acts on nerve endings, and it has higher efficacy than capsaicin in the activation 
and desensitization of nociceptors, depending on its concentration (Cairns, Sessle & Hu, 
1998; Szallasi, 2005; Fiorentino, Cairns & Hu, 1999). 
Piperine, the main pungent of black pepper (Piper nigrum) is employed for 
various purposes, since food condiments and to increase nutrient absorption, till as an 
metabolic accelerator (Szallasi, 2005). Piperine can be employed in the study of neuronal 
function by its ability to activate (Liu & Simon, 1996) or block noxious stimuli in sensory 
neurons of the trigeminal ganglion. The action of this agent is initiated by the activation of 
the transient receptor potential vanilloid 1 (TRPV1) (McNamara, Gunthorpe & Randall, 
2005), which presents a common binding site for other natural activating substances of the 
nerve fiber, such as capsaicin and resiniferatoxin (Szolcsanyi, 1983; Patacchini, Maggi & 
Meli, 1990; Szallasi & Blumberg, 1991). After activation of TRPV1, there is an influx of 
sodium and calcium ions into the sensory neurons (Marsh et al, 1987), and it begins the 
depolarization and axonal conduction of nociceptive stimuli (Patacchini, Maggi & Meli, 
1990). Due to its sensitivity to heat and protons (Caterina et al, 1997; Tominaga et al, 
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1998), the receptor acts as a molecular integrator of chemical, physical and thermal stimuli 
(Caterina et al, 1997). Furthermore, its expression in human sensory neurons involved in 
pain pathways and gastrointestinal function (Hayes et al, 2000; Ward et al, 2003) makes the 
TRPV1 a good target for pharmaceutical intervention. This interest is due to the possibility 
to develop new drugs that can directly act on this receptor for the treatment of various 
pathological conditions since from inflammatory and neuropathic pain till bladder 
dysfunction and irritable bowel syndrome (Szallasi & Appendino, 2004). 
The involvement of TRPV1 in the transmission of nociceptive information 
from peripheral nerve endings to the central nervous system (CNS) through the primary 
afferent neurons is duly proven, and studies indicate a broad pharmacological action of 
piperine as an agonist or antagonist for this receptor, depending its concentration (Yang et 
al, 2011; Szallasi, 2005). However, there are no studies that indicate the effective 
concentration of piperine to investigate, in an animal model, the effectiveness of 
nociceptive transmission of these nerve endings located in the Temporomandibular Joint 
(TMJ). 
Thus, the objective of this study was to verify, using an animal model, the use 
of piperine to induce nociception in TMJ region, and also, to determine the minimum 
concentration of this substance required for maximum nociceptive response in female rats 
after its application in TMJ. 
 
Materials and Methods 
 
A. Animals 
For this study, 48 female Wistar rats from Multidisciplinary Center for 
Biological Research (CEMIB – UNICAMP) were used. These animals were housed in 
plastic cages (05 per box) in a temperature-controlled environment (23 °C ± 1 °C), light 
and dark cycle of 12 hours (06 am - 06 pm) and access to water and food ad libitum. The 
rats remained in this condition until they reach maturity and weight (250-300 g) to start the 
research (Roveroni et al, 2001). This study was approved by the Local Ethics Committee 
on Animal Use (# 2633-1). 
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B. Determination of Hormonal Cycle 
The estrous cycle phases of rats were determined by the vaginal smear (Long & 
Evans, 1922) which consists in characterizing each phase based on the proportion between 
the epithelial cells, leukocytes and cornified cells (Mandl, 1951). After reaching maturity, 
vaginal secretion was collected between 7am and 8am, using an automatic micropipette 
(Micropipette automatic LabMate HT 20 μl), plastic tip (Axygen Scientific, Union City, 
CA, USA) and sterile saline (Braun, São Gonçalo, RJ, Brazil). This procedure was 
performed in a separate room. Each cage was transported at a time in order to prevent stress 
and increased aggressiveness of females that would be later evaluated (Marcondes et al, 
2002). 
To collect vaginal fluid, 10 µl of saline solution was aspirated and deposited the 
initial portion of the vaginal conduit, and the secretion obtained from each animal was 
placed on glass slides for examination under a light microscope (Binocular Biological 
Microscope N 101 B Coleman) with 40x objective lens. After this analysis, the animals that 
were in diestrous phase, in which the estrogen levels are low, with a predominance of 
leukocytes cells (Marcondes et al, 2002), were separated for the subsequent steps of the 
experiment. 
C. Application of Piperine 
The 48 animals used for this study were randomly divided into six groups: 
control and experimental groups (table 01). Each animal had the respective solution 
injected into the right TMJ region.  
Table 01: Distribution of animals in the control and experimental groups with the respective solutions, which 
were injected into the right TMJ. 
Groups Injected Solution 
Control (n = 8) control solution - 10% ethyl alcohol (Chemco - Indústria e Comércio Ltda, 
Campinas, SP, Brazil), 10% Tween 80 (Dynamic - Chemistry Contemporary 
Ltda, Diadema, SP, Brazil) and 80% sterile saline (Braun, São Gonçalo, RJ, 
Brazil) (Bölcskei et al, 2010; Bellinger et al, 2007). 
I (n = 8) 1 μg of piperine (Sigma-Aldrich, St. Louis, MO, USA) diluted in 100 ml of 
the control solution 
II (n = 8) 2 μg of piperine (Sigma-Aldrich, St. Louis, MO, USA) diluted in 100 ml of 
the control solution 
III (n = 8) 3 μg of piperine (Sigma-Aldrich, St. Louis, MO, USA) diluted in 100 ml of 
the control solution 
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IV (n = 8) 4 μg of piperine (Sigma-Aldrich, St. Louis, MO, USA) diluted in 100 ml of 
the control solution 
V (n = 8) 5 μg of piperine (Sigma-Aldrich, St. Louis, MO, USA) diluted in 100 ml of 
the control solution 
 
After the identification of the estrous cycle phase, animals were moved to the 
Laboratory of Pain of the Physiology Department of the Piracicaba Dental School, and kept 
into a free noise room and temperature controlled at 23 °C. Individually, the animals were 
placed in the mirror chamber (30x30x30 cm) for behavior analyses for a period of 10 
minutes without water and food, in order to accommodate themselves and reduce the stress 
that could interfere in the behavioral analysis (Roveroni et al, 2001). 
After this adaptation period, the animals were lightly anesthetized with 
halothane (Tanohalo - Cristália Pharmaceutical Chemicals Ltd., Itapira, SP, Brazil) in 
which 30 μl of the following solutions were injected: control solution (mixture of 80% of 
sterile saline, 10% Tween 80 and 10% ethyl alcohol) and 1, 2, 3, 4 or 5 µg of piperine 
diluted as previously mentioned, according to their respective group. These solutions were 
applied by the same examiner who performed the assessment of nociceptive behavior, 
although not know which group the animals belonged. 
For the injection of solutions, disposable 30-gauge needle (injected Dental 
Products, Sao Bernardo do Campo, SP, Brazil) (a needle for each animal) was coupled to a 
polyethylene tube (PE-50; Intramedic, Clay Adams, Becton -Dickinson, Franklin Lakes, 
NJ, USA), in which was attached to a Hamilton syringe for 50 µL (Hamilton, Reno, NV, 
USA). The needle was inserted in the posterior-anterior direction in the pre-auricular region 
on the intersection of imaginary lines drawn from palpebral commissure to the lower edge 
of the hearing canal and the tangent perpendicular line to the anterior portion of the conduit. 
The needle reached the upper portion of the lateral pole of the mandibular condyle, for 
subsequent deposition of the solution. 
 
D. Behavior Testing 
Tests for behavior analysis were performed between 8 am and 17 am, by a 
blinder and calibrated examiner (Kappa = 0,82) relative which group each animal 
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belonged. After injection of the solution, the animal was placed back into the mirrored 
chamber and quickly his conscience was reestablished to start the assessing of the 
nociceptive behavior. Each animal was evaluated for a period of consecutive 45 minutes 
divided into 9 blocks every 5 minutes. The nociceptive behavior consisted of rubbing the 
orofacial region (Clavelou et al, 1989 and 1995) on the right side (the region of application 
of the substances) and flinching the head (Roveroni et al, 2001). 
For each block of 5 minutes, it was recorded the seconds spent by the animal to 
rub the orofacial region and the number of times that the animal flinched the head. The 
head flinches followed an uniform pattern of 1 second duration and at the end, this behavior 
was also expressed in seconds, leaving both behaviors expressed in function of time 
(Roveroni et al, 2001). Thus, we evaluated the nociceptive behavior of the sum of 
behaviors performed by the rats.  
 
E. Statistical Analysis 
The data with homogeneity of variance were analyzed by one-way ANOVA 
and post hoc multiple comparisons were performed using Tukey-Kramer, with the 
significance level of 5%. The data are presented in figures and in the text as mean ± SEM. 
 
Results 
When analyzing the sum of nociceptive behaviors, head flinching and orofacial 
rubbing, the experimental groups II and V (130.87 ± 27.53, 125.00 ± 27.55, respectively) 
were significantly different when compared to the control group (61.87 ± 2.98) (Fig. 01). 
Comparing the experimental groups with each other, even in figure 02, groups II and V 
differed significantly from group I (66.250 ± 3.480). The highest means of the sum of the 
nociceptive behavior was at concentration of 2 x 10
-2
 µg/ml and even with the increased 
concentration of piperine in the solution, there was a decrease in the sum of the behaviors 
in groups III and IV. In group V, there was a new peak in the sum of these behaviors, 
although no significant difference was observed in relation to group II. 
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Different piperine concentrations had no significant effect (P <0.05, Tukey-
Kramer) in the flinching when comparing experimental and control groups (Fig. 02).  
 
 
 
For the orofacial rubbing behavior, as evident in Figure 02, the groups that 
received 2 μg and 5 μg showed significant difference (100.37 ± 30.43, 100.00 ± 27.82, 
respectively) in the control group (33.37 ± 5.74). Among the experimental groups, it can be 
observed significant difference between those same groups and the group I which received 
1 μg (26.125 ± 6.112). 
The injection of piperine on the TMJ induced only one peak in the sum of 
nociceptive behavior, as shown in Figure 03 by the group II, in the course of 45 minutes of 
the analysis (Fig. 03). The behaviors sum showed increasing in the course of time to reach 
the maximum value between the periods of 20-25 minutes. Subsequent to this peak, there 
was a decline until reaching a plateau in times of 35-40 and 40-45 minutes. On the other 
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hand, the control group exhibited an alternation of peaks during the 45 minutes of 
evaluation. 
 
  
  
Evaluating separately the nociceptive behaviors (head flinching, orofacial 
rubbing) and the sum of the behaviors of the group that received 2 μg, different pattern in 
the course of time was observed (Fig. 04). The behavior of head flinching showed almost 
constant levels, with values lightly greater in the first half of the total time. Thus, the 
differing from the orofacial rubbing and the sum of behaviors, both showed increasing 
profiles until they reached the peak at half the total time of the assessment and subsequent 
descent. 
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Fig. 04 – Time course of nociceptive behavior of 
group II (2 µg) characterized by head flinching and 
orofacial rubbing and the sum of the behaviors, 
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bars indicated the SEM. 
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Discussion 
Pain is a sensory modality response to various noxious, chemical, physical and / 
or thermal stimuli, in which nociceptive primary afferent neurons detect and conduct 
nervous impulses to higher centers responsible for processing this information (Sessle, 
Iwata & Dubner, 2008; Caterina & Julius, 2001; Caterina et al, 1997). Conditions of TMJ 
pain are considered important manifestations of changes in this joint, but its pathogenesis, 
diagnosis and treatment remain poorly understood (Roveroni et al, 2001). As a result, the 
development of experimental models becomes important to clarify the mechanisms related 
pain conditions. 
In this study, the animals in the experimental group II that received 0,02 µg/ml 
of piperine solution showed the highest average of orofacial rubbing behavior, differing 
from the control group and the experimental group I. Groups III and IV, which received 
solutions with higher concentrations showed a reduction in mean values for this behavior, 
possibility because of the piperine action in desensitize the TRPV1. In group V, an increase 
of the average values was observed, while it was not enough to overcome the values 
reached by the group II. This behavior may have occurred as a result of some secondary 
mechanism of piperine as increased release of neuropeptides (Geppetti & Trevisani, 2004, 
Black, 2002; Caterina & Julius, 2001) that activated the receptor, but not enough to 
overcome the averages of the group that received 2 µg. 
The higher prevalence of TMD pain in women in the reproductive phase is 
suggested by the influence of hormonal fluctuation in pain perception (LeResche, 1997). 
The average levels of pain intensity rise at the end of the cycle and reach the peak during 
the first three days of the menstrual cycle and during ovulation (LeResche, 1997). Because 
of these aspects, researches related to pain are performed in female animals and nociceptive 
behavior assessment is performed during the diestrous hormonal phase (Marcondes, 
Bianchi & Tanno, 2002). 
The present study showed the nociceptive behavior of female rats characterized 
by head flinching and rubbing the orofacial region (Roveroni et al, 2001; Clavelou et al, 
1995, 1989) after injection of different concentrations of piperine. The selection of piperine 
as promoting substance of the nociceptive stimulus is justified because it has more efficacy 
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than capsaicin for both activation and desensitization of this receptor in experimental 
animals and in vitro (Szallasi, 2005; McNamara, Gunthorpe & Randall, 2005; Liu & 
Simon, 1996). It is suggested that activation of TRPV1 mediated by piperine involves a 
larger number of binding sites than capsaicin, by recruiting more subunits in TRPV1 in the 
input mechanism or by having other binding sites on this receptor (McNamara, Gunthorpe 
& Randall, 2005). Besides this, TRPV1 has some features, such as expression in the C fiber 
and activation by pro-inflammatory cytokines that make this receptor suspect to be 
involved in TMD.   
The TRPV1, a channel non-selective cation permeable to sodium and calcium 
(Caterina et al, 1997) is expressed in peptidergic and non-peptidergic neurons of the 
trigeminal ganglion (TG) and dorsal root ganglion (DRG), but is more associated with non-
myelinated fibers than the myelinated sensory root of the brainstem (Yang et al, 2011; 
Immke & Gawa, 2006; Ward et al, 2003; Hou et al, 2002; Ichikawa & Sugimoto, 2001; 
Valtschanoff et al, 2001; Hayes et al, 2000; Guo et al, 1999). These afferent neurons, 
which express TRPV1 and innervate the orofacial region, are projected to the sensory 
trigeminal nucleus, most predominantly in laminae I and the outer portion of the laminae II 
of Caudal Trigeminal Nucleus (CTN) (Bae et al, 2004), the main local to relay of 
nociceptive information from the orofacial region (Sessle, Iwata & Dubner, 2008). Little is 
known about the organization of synaptic terminals of axons that express TRPV1 in CTN, 
as well as its predominance by non-myelinated fibers in the sensory root of the TG, its 
arrangement in the CTN and its connectivity with one or two postsynaptic dendrites (Yeo et 
al, 2010). 
The polymodal nature of TRPV1 is the result of their sensitivity to surrounding 
pH and temperature variations by extracellular acidification (protons) as well as 
endogenous activators such as pro-inflammatory mediators, as well as piperine, capsaicin 
and resiniferatoxin (McNamara, Randall & Gunthorpe, 2005; Geppetti & Trevisani, 2004; 
Ward et al, 2003; Caterina & Julius, 2001; Jordt, Tominaga & Julius, 2000; Szallasi & 
Blumberg, 1991; Tominaga et al, 1998). Activation of TRPV1 results in a rapid increase of 
the levels of intracellular Ca
+2
 (Cortright & Szallasi, 2004; Geppetti & Trevisani, 2004), 
and causes depolarization and propagation of the action potential to the dorsal horn (Immke 
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& Gawa, 2006; Geppetti & Trevisani, 2004). The importance of these receptors was 
demonstrated by their involvement in post-inflammatory hyperalgesia, and it stimulates 
pharmaceutical research to identify new antagonists for TRPV1 (Bley, 2004; Szallasi & 
Appendino, 2004; Valenzano & Sun, 2004). Associated with this, its expression is 
increased in many human diseases, including inflammatory bowel disease, disorders of 
intestinal motility (fecal urgency), and chronic pain conditions such as chronic breast pain 
(Caterina & Julius, 2001). The Ca
+2
 influx into the nerve endings, after sensitization 
TRPV1 causes a local release of neuropeptides, such as gene-related peptide calcitonin 
(CGRP), and substance P (SP), which causes inflammatory responses, as neurogenic 
inflammation (Geppetti & Trevisani, 2004, Black, 2002; Caterina & Julius, 2001). 
However, it seems that the neuronal response to the transmission of nerve 
impulse after stimulation of TRPV1 receptor is dose dependent of stimulatory agent. In the 
present study, piperine was used as a noxious agent. While in the higher concentration this 
substance inhibits the receptor, at lower concentrations apparently stimulates the 
conduction through the receptor (Szallasi, 2005). However, there are no studies that 
identify the optimal concentration of this agent to promote the nociceptive stimulus in 
animal models for studies of TMD. Therefore, in the present study it was used various 
concentrations of piperine in order to identify the most effective dose for this purpose. It 
was observed that injection of different concentrations of piperine promoted nociceptive 
responses in different intensities. Analyzing separately the behaviors data, the head 
flinching behavior was similar in all groups, with no statistical difference. Even for the 
experimental group III, that showed the highest mean values, although no difference was 
observed, when compared with the control group or the others experimental groups. This 
finding suggests that the nociceptive behavior of head flinching may have been influenced 
more by increasing the volume inside the joint (Hu et al, 1994) rather than to the action of 
piperine, since all groups received the same volume of the respective solution. 
We conclude that piperine can be used as a substance in an animal model to 
promote nociceptive behavior in the TMJ region, and the minimum effective concentration 
to get the highest nociceptive response is 0,02 µg/ml.. In future studies, it will be possible 
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to investigate the role of TRPV1 in the underlying mechanisms of pain associated with 
TMD. 
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Abstract: The aim was to analyze the animal behavior of orofacial pain in 
temporomandibular joint region in females Wistar after the injection of different 
concentrations of piperine to determinate its minimum effective concentration in: chronic 
inflammation, chronic stress and the association of both conditions. The chronic 
inflammation was induced by Complete Freund’s Adjuvant and the stress exposure 
followed a chronic model during 40 days. One hundred forty four female rats were 
randomly divided in tree groups (n=48), according to the three proposed conditions. Each 
group was divided in six groups, and each subgroup received an injection in the right TMJ 
region of 30µl of one of the following solutions: control solution – ethyl alcohol, Tween 80, 
sterile saline and the other experimental subgroups: 1; 2; 3; 4 or 5 µg of piperine diluted in 
100 ml of ethyl alcohol of the control solution. The rats in diestrous cycle, after the 
injection of one of the solutions, were evaluated for the nociceptive behavior, which 
consisted in counting how many times the animals flinched their head and how long they 
rubbed their orofacial region. As the first behavior followed a uniform pattern of 1 
movement per second, both behaviors were expressed in seconds. The data were submitted 
to the two- way ANOVA test and Tukey-Kramer test (post-hoc, P<0.05). For the 
inflammation group, the control and the others experimental subgroups of piperine injected 
animals, there was significant difference among the groups that received 0,04 µg/ml for all 
the behavior and the sum of them. For the stressed group, the same significant difference 
was noted between the subgroup that received 0,04 µg/ml for all the behavior and the sum 
of them. For the association group, no difference was observed among the groups. The 
results suggest that, for chronic inflammation and chronic stress, the minimum effective 
concentration to causes TMJ pain was 0,04 µg/ml and also it can be used as a model in 
studying of orofacial pain. 
Keywords: Chronic Inflammation - Chronic Stress - Temporomandibular Joint - Piperine – 
Nociceptive Behavior. 
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Introduction 
Pain is defined as an unpleasant sensory and emotional experience associated 
with actual or potential damage tissue (Merskey & Bogduk, 1994). Many studies of chronic 
pain in humans are related to assessment, perception and response to pain, which involves 
the emotional-affective system, cognition, learning principles, pain behavior and social, 
environmental and biological factors, and vary considerably from patient to patient. 
(Suvinen & Reade, 1995; Melzack, 1999). All these factors explain the different pain 
responses that patients show for similar clinical situations. Besides ethics questions, all 
these factors may confound pain clinical studies, justifying the development of animals’ 
research. 
Temporomandibular Disorder (TMD) pain is the most evidenced symptom, 
involved in Temporomandibular Joint (TMJ), masticatory muscles or both (Cairns, 2010; 
Scrivani et al, 2008; LeResche et al, 2003; LeResche, 1997). Besides the muscle and/or 
joint pain, TMD may be associated to headache, limitation of mandibular movements and 
high level of pain disability (de Leeuw, 2008; Scrivani et al, 2008; Wadhwa & Kapila, 
2008; Yap et al, 2002). 
Orofacial pain is more prevalent in females during the reproductive age 
(Scrivani et al, 2008; LeResche, 1997; Lipton et al, 1993), specially during mandibular 
function or under palpation (LeResche, 1997). This high prevalence in adult women 
indicate that biological, behavioral, psychological and social problems associated with 
female increase the risk of pain in the TMJ region (LeResche, 1997). The TMD, as well as 
other diseases, has its onset resulting from the interaction between individual factors like 
individual social context (Schimitter et al, 2010). 
Although the etiology of TMD has not been established, psychological aspects 
have been associated with predisposition, initiation and perpetuation of TMD (Suvinen et 
al, 2005; Lindroth et al, 2002; List et al, 2001), in which stress, depression and multiple 
somatic symptoms are risk factors (LeResche, 1997). Stress seems to exert an important 
influence on the development of pain (Fricton, 2007) and intensity of symptoms in TMD 
(Gameiro et al, 2006). The stress response and the mechanism of pain modulation have 
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some common molecules, and stress may be involved in biological process of pain 
(Gameiro et al, 2006). 
Similarly to stress, inflammatory processes, as the Internal Joint Disorders, 
promote the release of proinflammatory cytokines in the synovial fluid, such as interleukins 
(IL) -1 and 6, tumor necrosis factor (TNF) -α, IL -6 and others (Takahashi et al, 1998; 
Whiteside, 1994). Those cytokines contribute to the synovitis pathogenesis, degenerative 
changes in TMJ cartilage and bone, and interfere in the clinical symptoms of TMJ pain 
(Takahashi et al, 1998). In the synovial fluid, cytokines stimulate production, release and 
activation of enzymes that degrade cartilage matrix and lead to the production of 
inflammatory mediators such as prostaglandins and leukotrienes (Pelletier et al, 1993; 
Arend & Dayer, 1990). The symptom becomes prolonged and resistant to treatment 
(Cairns, 2010). The persistence pain results a peripheral mechanisms within the joint that 
prolongs the sensitization of neurons in the central nervous system (CNS), resulting in local 
increase of calcitonin gene-related peptide (CGRP), substance P, and proinflammatory 
neuropeptides (Cairns, 2010). It can be induced by tissue injury caused by inflammatory 
processes, but also is associated to excessive loads on the joint under stress conditions 
(Cairns, 2010). 
Through the application of different concentration of piperine, this experimental 
research in animals aimed to: (i) develop an experimental model of pain in the TMJ under 
chronic inflammation, under chronic stress condition, and under the association of both 
conditions; and (ii) compare the influence of these conditions in the perception of the 
nociceptive stimuli. 
 
Materials and Methods 
 
Animals 
For this study, 144 female Wistar rats were used, from the Multidisciplinary 
Center for Biological Research (CEMIB - University of Campinas, Unicamp, Brazil). This 
study was approved by the Local Ethics Committee on Animal Use (# 2633-1). The 
animals were kept in a room with controlled temperature (23 ± 1 °C), and housed in plastic 
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cages (five animals per cage) with 12 h light/dark cycle (lights at 07:00 am) and availability 
of feed and water ad libitum for at least two months before the experiments, until they 
reached the ideal weight for onset of behavior assessment (200-250 g). 
 
Experimental design 
After reaching body weight of 200-250g the 144 animals were randomly 
divided into three groups: Group I (n = 48) that was induced by chronic inflammation in the 
right TMJ with Complete Freund's Adjuvant (CFA), Group II (n = 48), where the animals 
were subjected to chronic stress for 40 days, Group III (n = 48), the animals were submitted 
to both conditions, chronic TMJ inflammation and chronic stress. Each group was divided 
into six other subgroups (n = 8), in which one of the following solutions was injected: 80% 
sterile saline solution, 10% Tween 80 and 10% ethanol (control subgroup); 0; 1; 2; 3; 4 or 5 
μg of piperine diluted in 100 ml of 80% sterile saline, 10% Tween 80 and 10% ethyl 
alcohol. 
 
Articular Inflammation 
The rats were initially anesthetized with a mixture of 55 mg/kg ketamine 
(Dopalen, Vetbrands Ltda Brazil, Goiania, GO) and 5.5 mg/kg xylazine (Rompum, Bayer, 
São Paulo, SP) (Flake et al, 2005). Chronic inflammation of the right TMJ was induced by 
intra-articular injection of 50 µl CFA (15 µg dead heat mycobacterium) (Sigma-Aldrich, St. 
Louis, USA) in an oil/saline suspension (1:1) (Wang et al, 2009). For injection of all intra-
articular solutions, a cannula was used, in which one extremity was connected to a 
disposable needle 0.45 mm x 13 mm, and the other to 50 µl Hamilton syringe (Hamilton 
Company, Reno, NV, USA) (Roveroni et al, 2001). For evaluation of animal behavior, a 
period of 10 to 12 days was required for the development of chronic inflammation in the 
animal TMJ (Hutchins et al, 2000). 
 
Stress Exposure 
The animals were stressed based on a chronic model during 1 h a day, five days 
per week for 40 days (Ely et al, 1997). The procedure was performed by placing the animal 
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inside a small plastic perforated box to isolation (Gameiro et al, 2005). The process was 
conducted in a quiet room separate from 08:00 to 10: 00 h. 
 
Analysis of Phase Hormonal Cycle 
The diestrous phase of the estrous cycle was identified by the rat vaginal 
secretion, characterized by the predominance of leukocytes (irregular cells) (Mandl, 1951). 
Briefly, in the morning, before starting the experiment, vaginal smear was collected using 
an automatic micropipette and 10 ml of saline (0.9% NaCl). After arresting the rat, the 
pipette tip was inserted into the vagina, released saline and the vaginal secretion was 
aspirated. The fluid collected was placed on a glass slide and observed under a microscope 
40x objective lens (Marcondes et al, 2002). The animals in the diestrous phase followed for 
the next stage of the experiment, whereas the others were evaluated on subsequent days 
until they were in the hormonal phase of interest. Therefore, TMJ pain in women is higher 
during periods of low circulating levels of ovarian hormones (LeResche et al, 2003). 
 
Piperine Injection 
The six solutions of piperine were prepared from commercially available stock 
of piperine (Sigma-Aldrich, St. Louis, USA) containing 0, 1, 2, 3, 4 or 5 µg diluted in 10% 
ethyl alcohol (Chemco, Ltda, Sao Paulo, Brazil), 10% Tween 80 (Dynamic, Ltda, Sao 
Paulo, Brazil), and sterile saline (Med Flex ®, Rio de Janeiro, Brazil), totaling a final 
volume of 100 ml for each solution. 
Animals in the diestrous phase of the hormonal cycle were randomly distributed 
into subgroups, and anesthetized with halothane in order to inject into the TMJ region one 
of this different concentrations of piperine solution: 0 (ethyl alcohol, Tween 80 and sterile 
saline, control subgroup) (n = 8), 1x10
-2
 µg/ml (n = 8), 2 x10
-2
 µg/ml (n = 8), 3 x10
-2
 µg/ml 
(n = 8), 4 x10
-2
 µg/ml (n = 8), 5 x10
-2
 µg/ml (n = 8). The injections were performed by an 
examiner who was blinded to the experimental design, which determined the injection site 
by palpation of the zygomatic arch area, and the needle was inserted just below the edge of 
the posterior lateral condyle. The needle was introduced in the antero posterior direction 
until reaching the posterior lateral condyle surface, in which 30 µl of the selected solution 
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was injected. This procedure used a cannula prepared as previously described (Roveroni et 
al, 2001). 
 
Assessment of Nociceptive Behavior 
Rats nociceptive behavior was evaluated by a blinded calibrated examiner 
during the light phase (8:00 - 17:00 h),. The animals were individually placed in a mirrored 
chamber (30 x 30 x 30 cm) during 10 minutes for a habituation, and no feed or water was 
available. After this period, the animals were lightly anesthetized by inhalation of halothane 
(Sigma-Aldrich, St Louis, USA) for the TMJ injection. One investigator performed all the 
different injections in the right TMJ, using a solution of 30 µl of 0, 1, 2, 3, 4 or 5 µg of 
piperine diluted in 100 ml of control solution, depending on the group. After recovering 
consciousness, the animal was placed back into the mirrored chamber for nociceptive 
behavior evaluation. The nociceptive behavior characterized by rubbing the orofacial 
region (Clavelou et al, 1995) and flinching the head (Roveroni et al, 2001) was counted for 
45 minutes divided into 9 blocks of 5 minutes. For each block, the amount of time that the 
animal spent rubbing the orofacial region was quantified in seconds. The head flinches 
were counted in number of times that happened, and it followed a uniform pattern of a 
second duration per movement (Gameiro et al, 2005; Roveroni et al, 2001). The behaviors 
were quantified in seconds (Roveroni et al, 2001). The nociceptive behaviors counted 
during the 45 minutes observation were evaluated separately, and then their sum was also 
used for statistical analysis (Roveroni et al, 2001). After the behavior test, and according to 
the International Association for the Study of Pain, all animals were sacrificed. 
 
Statistical Analysis 
For evaluation of nociceptive behaviors, the data with homogeneity of variance 
were compared by two-way ANOVA, and multiple post-hoc comparisons were performed 
by Tukey-Kramer, with the significance level of 5%. The data were presented as mean and 
standard deviation. 
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Results 
 
Nociceptive behavior by Piperine under the condition of Articular Inflammation 
Chronic joint inflammation induced by injection of CFA showed statistically 
significant difference in head flinching behavior between 5x10
-2
 µg/ml (69.50 ± 16.44) and 
control subgroups (40.13 ± 15.06). There was difference among the 1x10
-2 
(21.63 ± 5.15); 
4x10
-2
 (53.87 ± 19.61) and 5x10
-2
 µg/ml (69.50 ± 16.44) experimental subgroups as well. 
The orofacial rubbing behavior had no significant difference among the subgroups. For the 
sum of the behaviors, there was significant difference among control (52.85 ± 17.46) and 
4x10
-2
 (105.37 ± 22.64) and 5x10
-2
 µg/ml (115.50 ± 35.14) subgroups, as well as 1x10
-2
 
(62.75 ± 21.67) and 5x10
-2
 µg/ml subgroups (P <0.05) (Fig. 1 and 2). 
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Fig 1: Mean values of behaviors of head flinching 
and orofacial rubbing after injection into the TMJ 
region of increasing concentrations of piperine in 
the presence of chronic inflammation. The error bar 
indicates the SEM. (*) indicates significant 
difference when compared with the control 
subgroup (0 μg piperine), and (#) indicates 
significant difference among the experimental 
subgroup (P <0.05 for all comparisons, test Tukey-
Kramer). 
* 
* 
* 
Fig 2: The mean of the sum of nociceptive 
behaviors, head flinches and orofacial rubbing after 
injection of different concentration of the solution 
of piperine in the right TMJ in the presence of 
chronic inflammation. The error bar indicates the 
SEM. The significant difference between the 
subgroups is shown (*) when compared with the 
control subgroup. (#) indicates significant 
difference between the experimental subgroups (P 
<0.05 for all comparisons, Tukey-Kramer).  
# 
# 
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Nociceptive behavior by Piperine under the Condition of Chronic Stress 
The results presented in Figures 3 and 4 show that the head flinching behavior 
among control (49.87 ± 10.70) and 4x10
-2
 (85.87 ± 19.21) and 5x10
-2
 µg/ml (83.63 ± 
12.69) of piperine subgroups were statistically different (P <0.05).  
 
 
 
 
 
Nociceptive behavior by Piperine under the Condition of the Association of Articular 
Inflammation and Chronic Stress 
The association of inflammatory conditions and chronic stress had significant 
difference between control (60.75 ± 17.54) and 5x10
-2
 µg/ml (92.87 ± 18.35) subgroups for 
head flinching behavior. A significant statistically difference between 1x10
-2
 (65.13 ± 6.64) 
and 5x10
-2
 µg/ml subgroups was also observed (P <0.05). 
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Fig 3:  Results of head flinching and orofacial 
rubbing behaviors after injection into the TMJ 
region of increasing concentrations of piperine on 
the condition of chronic stress. The error bar 
indicates the SEM. For head flinching (*) indicates 
significant difference when compared with the 
control subgroup (0 μg piperine) (P <0.05 for all 
comparisons, Tukey-Kramer). 
 
Fig 4: Representing the sum of nociceptive 
behaviors after injection of different concentration 
of the solution of piperine on the condition of 
chronic stress. The error bar indicates the SEM (P 
<0.05 for all comparisons, Tukey-Kramer). 
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Analysis of Nociceptive Behaviors in Different Concentrations of Piperine under Chronic 
Inflammation, Chronic Stress and Association of both Conditions 
The sub group that received 5x10
-2
 µg/ml showed the highest mean of head 
flinching behavior (P <0.05) in the combination of both treatment conditions (chronic 
inflammation and stress) (Table 1). 
 
 
  
Concentration 
(x 10-2 µg/ml) 
  Condition   
Chronic Inflammation Chronic Stress Association 
0  40.13(±15.06) Aabc 49.87(±10.70) Ab 60.75 (± 17.54) Ab 
1 21.63(±5.15) Bc 59.37(±13.66) Aab 65.13 (± 6.64) Ab 
2 44.25(±23.20) Aabc 65.13(±15.60) Aab 70.63 (± 6.93) Aab 
3 34.87(±19.70) Bbc 55.37(±11.71) ABb 68.87 (± 8.69) Aab 
4 53.87(±19.61) Bab 85.87(±19.21) Aa 73.63 (± 19.83) ABab 
5 69.50(±16.44) Aa 83.63(±12.69) Aa 92.87 (± 18.35) Aa 
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Fig 5: Results of nociceptive behaviors, head 
flinching and orofacial rubbing after injection into 
the TMJ region of increasing concentrations of 
piperine in the join chronic inflammation and 
stress. The error bar indicates the SEM. For head 
flinches (*) indicates significant difference when 
compared with the control subgroup (0 μg piperine) 
and (#) indicates difference with the 1x10-2 µg/ml 
subgroup (P <0.05 for all comparisons, Tukey-
Kramer). 
 
Fig 6: The mean of the sum of nociceptive 
behaviors, head flinching and orofacial rubbing, 
after injection of different concentration of the 
solution of piperine in the join condition of chronic 
inflammation and stress. The error bar indicates the 
SEM. (P <0.05 for all comparisons, Tukey-
Kramer).  
* # 
# 
Table 1: Mean (± standard deviation) of the head flinching behavior after the injection of piperine in different concentrations and evaluated in 
different conditions of chronic joint inflammation, chronic stress and combination of both (P <0.05). 
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The average values of the orofacial rubbing behavior had no difference among 
treatment conditions in different piperine concentrations, as shown in Table 2. 
  
 
    Condition   
Concentration (x 10-2 µg/ml) Chronic Inflammation Chronic Stress Association 
0 14,71 (± 7,54) Aa 35,75 (± 12,69) Aa 41,37 (± 19,78) Aa 
1 41,13 (± 20,81) Aa 36,87 (± 17,96) Aa 32,87 (± 6,75) Aa 
2 34,13 (± 25,59) Aa 35,25 (± 19,58) Aa 42,87 (± 17,05) Aa 
3 35,87 (± 16,14) Aa 42,00 (± 10,84) Aa 28,25 (± 18,11) Aa 
4 51,50 (± 28,73) Aa 44,75 (± 20,53) Aa 44,50 (± 22,63) Aa 
5 46,00 (± 22,53) Aa 48,25 (± 27,25) Aa 34,50 (± 18,45) Aa 
 
The table 3 shows the average values of the sum of the nociceptive behaviors.  
The 5x10
-2
 µg/ml subgroup in the chronic stress exhibited higher means (P < 0.05). 
 
 
    Condition   
Concentration (x 10-2 µg/ml) Chronic Inflammation Chronic Stress Association 
0 52,85 (± 17,46) Bc 85,63 (± 17,03) Aab 102,13 (± 22,74) Aa 
1 62,75 (± 21,67) Abc 96,25 (± 15,03) Aa 98,00 (± 10,51) Aa 
2 78,37 (± 32.08) Aabc 100,37 (± 15,50) Aa 113,50 (± 17,96) Aa 
3 70,75 (± 24,91) Aabc 97,37 (± 17,50) Aa 97,13 (± 23,97) Aa 
4 105,37 (± 22,64) Aab 130,63 (± 31,22) Aa 118,13 (± 6,20) Aa 
5 115,50 (± 35,14) Aa 131,87 (± 35,05) Aa 127,37 (± 22,44) Aa 
 
Discussion 
The TMD pain is a very common symptom, involving the masticatory muscles 
and/or joint (Yap et al, 2002), with higher incidence in women, in which female hormones 
are one of the possible factors involved in the occurrence (Cairns, 2010). Besides the 
biological damage caused by the maintenance of pain sensation and imbalance in the 
modulation system, chronic pain often affects patients in a variety of psychosocial and 
behavioral comorbid conditions, such as impaired of life quality, stress, depression and 
Tabela 2: Mean (± standard deviation) of the orofacial rubbing behavior after the injection of piperine in different concentrations and evaluated 
in different conditions of chronic joint inflammation, chronic stress and combination of both (P<0.05). 
Tabela 3: Mean (± standard deviation) of the sum of the nociceptive behaviors after the injection of piperine in different concentrations and 
evaluated in different conditions of chronic joint inflammation, chronic stress and combination of both conditions (P<0.05). 
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sleep disorders (Yunus, 2008). The central sensibilization, responsible for long-term pain in 
patients, is caused by the high magnitude and/or repetitive nociceptive impulses that can 
cause peripheral and central neuronal changes, leading to maintenance and exacerbation of 
pain sensation (Conti et al, 2003). This may explain the failure of treatment in some 
patients with TMD. 
Patients with joint changes, such as disc displacement, show an increased 
expression of CGRP and substance P (Sato et al, 2007) into the TMJ, and a positive 
correlation with the intensity of pain (Cairns, 2010). Functional overloading on the joint 
can induce severe and progressive joint damage that promote increased expression of these 
neuropeptides (Tanaka et al, 2008), that contribute to the peripheral mechanisms of pain 
(Cairns, 2010). The TMJ inflammation results from the release of many proinflammatory 
cytokines, especially tumor necrosis factor-α (TNF-α) and interleukin (1, 6, 12 and 17) 
(Vernal et al, 2008), which facilitate the release of pro-nociceptive compounds which 
include leukotriene B4, prostaglandin (PG) E2, bradykinin, histamine (Cairns, 2010). The 
excitation of TMJ nociceptors by these pro-nociceptive compounds further enhances the 
release of CGRP and substance P (Cairns, 2010). There is also a strong relationship 
between joint pain and the detection of IL-1β in synovial fluid (Takahashi et al, 1998). 
Based on data from this experimental research, the minimum concentration to 
provide a nociceptive behavior in the presence of chronic joint inflammation was 4 x 10
-2
 
µg/ml of piperine. It is known that during inflammation conditions, the expression of 
TRPV1 is increased, as pro-inflammatory substances released during this process as well as 
low pH have the ability to activate TRPV1 (Di Marzo et al, 2002). Besides this, activation 
of other membrane receptors by inflammatory mediators such as bradykinin and TNF can 
lead to activation of TRPV1 (Prescott & Julius, 2003). It is therefore suggested that, higher 
amount of active receptors, the greater the amount of piperine can bind to TRPV1 and 
hence increases the nociceptive responses. This increased expression of TRPV1 justifies 
pharmacological studies in order to block the activation of this receptor, which is useful in 
cases of chronic pain and inflammatory hyperalgesia (Szallasi & Appendino, 2004). 
Psychological factors, such as stress and depression, are related to the TMD 
(Sullivan et al, 2001) in the process of pain perception (Gameiro et al, 2006; Gamsa, 1994) 
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and implicated in the predisposition, initiation and perpetuation of TMD (Rollman & 
Gillespie, 2000; List & Dworkin, 1996). The stress is related to TMD pain because they can 
induce muscle hyperactivity and parafunctional habits, and also interfere in pain perception 
and response to conventional therapies in the dysfunction treatment (Dworkin & Turner, 
2004; Rollman & Gillespie, 2000). In TMD, the orofacial pain is a potent stimulus for 
stress, as many patients have hyperactivity of the hypothalamic-pituitary-adrenal axis 
(Gameiro et al, 2006). 
In this study, the group of chronic stress also exhibited the greatest results of 
nociceptive behavior in the minimum concentration of 4 x 10
-2
 µg/ml of piperine. We 
confirm that the TMD pain seems to be influenced by psychological changes (Dworkin, 
Huggins et al, 2002). The study of stress in TMD pain conditions is critical due to its strong 
influence on pain perception and response to treatment. Comparing the conditions of 
chronic inflammation and chronic stress in the same piperine concentration, 4 x 10
-2
 µg/ml, 
the results exhibited significant difference only for head flinches. But even though, the 
means values in chronic stress were higher than the chronic inflammation group, showing 
the stress influence over the pain perception. 
The association of chronic inflammatory and stress conditions had no 
significant difference between the subgroups, except 5 x 10
-2
 µg/ml of piperine subgroup 
had only statistics difference for the head flinching behavior. This can be explained by the 
presence of common mediators of stress and inflammation conditions competing for the 
same binding site of piperine, so that the increase in the piperine concentration had no 
effect on nociceptive response. Another possible explanation is that many of the molecules 
that are involved in stress responses are the same as those associated with pain modulation, 
so that stress may influence the pain biological processes (Gameiro et al, 2006). Differing 
what was thought initially, group III didn't show the sum of the inflammation and stress 
influence over the nociceptive responses. And, as it didn't exhibited significant difference 
between the groups II and III, it can suggest that the stress presence, by itself, influenced 
the pain perception. 
Pain is a complex and multidimensional experience, envolving sensory-
discriminative, cognitive, emotional and motivational dimensions (Wadhwa & Kapila, 
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2008). Thus, pain conditions in the orofacial region can’t be treated only for remission of 
symptoms, but also on factors that may affect the pain perception and response to 
subsequent therapy. According to the data obtained in this study, we can conclude that: (i) 
previous chronic inflammation condition, the minimum concentration to provide enhanced 
nociceptive behavior on orofacial region was 4 x 10
-2
 µg/ml of piperine; (ii) in chronic 
stress condition, the concentration of 4 x 10
-2
 µg/ml of piperine also exhibited significant 
differences when compared to its control subgroup; (iii) in the presence of chronic 
inflammation and stress, there was no significant difference among the different piperine 
concentrations on nociceptive response, but the concentration of 5 x 10
-2
 µg/ml showed the 
highest mean in this condition; (iv) comparing the conditions, the chronic inflammation 
group exhibited the lower values, suggesting a higher influence of the stress over the pain 
perception; (v) and the presence of chronic inflammation and stress in the group III didn’t 
show the sum of the influence of these conditions on the nociceptive responses. 
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Conclusão 
Baseado nos dados obtidos neste estudo, para avaliar comportamento nociceptivo na região 
da ATM por meio da ativação do TRPV1 usando diferentes concentrações de piperina, 
pode-se concluir que: 
 Na condição de normalidade na ATM de ratas, a concentração mínima efetiva 0,02 
µg/ml de piperina pode ser utilizada para promover resposta nociceptiva;  
 Na presença de inflamação crônica articular, a concentração mínima efetiva para 
causar resposta nociceptiva na região da ATM foi de 0,04 µg/ml de piperina; 
 Em condições de estresse crônico, a solução de 0,04 µg/ml de piperina foi a 
concentração mínima efetiva para desencadear uma resposta nociceptiva na ATM; 
 Na presença da associação das condições de inflamação e estresse crônicos não 
apresentou diferença estatística significante entre os grupos, mesmo a solução de 
0,05 µg/ml tendo apresentado os maiores valores. 
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